Published in N Engl J Med on May 13, 2010
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2015) 1.47
The Treatment of Cushing's Disease. Endocr Rev (2015) 1.35
Management of Cushing disease. Nat Rev Endocrinol (2011) 1.26
Cushing's syndrome: epidemiology and developments in disease management. Clin Epidemiol (2015) 1.02
Medical management of Cushing's disease: what is the future? Pituitary (2012) 0.99
Cushing's disease. Orphanet J Rare Dis (2012) 0.98
Treatment of Cushing disease: overview and recent findings. Ther Clin Risk Manag (2010) 0.98
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol (2013) 0.97
Quality of life and other outcomes in children treated for Cushing syndrome. J Clin Endocrinol Metab (2013) 0.95
Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. J Clin Endocrinol Metab (2015) 0.91
The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens (2015) 0.88
Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics. J Oncol (2012) 0.82
Pasireotide. Nat Rev Drug Discov (2012) 0.81
Update in the medical therapy of Cushing's disease. Curr Opin Endocrinol Diabetes Obes (2013) 0.80
Pituitary tumors in 2010: a new therapeutic era for pituitary tumors. Nat Rev Endocrinol (2011) 0.77
Treatment Options in Cushing's Disease. Clin Med Insights Oncol (2012) 0.77
New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy. J Neurooncol (2013) 0.76
Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. Pituitary (2016) 0.75
Clinical use of pasireotide for Cushing's disease in adults. Ther Clin Risk Manag (2015) 0.75
Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Adrenocorticotropic Hormone Production and Tumorous Corticotroph Cell Growth in AtT20 Cells. Chin Med J (Engl) (2016) 0.75
The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study. Int J Endocrinol (2016) 0.75
BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. Sci Rep (2017) 0.75
Role of "old" pharmacological agents in the treatment of Cushing's syndrome. J Endocrinol Invest (2016) 0.75
Disappearance of pituitary macro adenoma with combination of ketoconazole and cabergoline treatment: an unusual case of Cushing's syndrome with interesting findings. BMJ Case Rep (2012) 0.75
Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms. Front Surg (2016) 0.75
Clinical Guidelines for the Diagnosis and Treatment of Cushing's Disease in Korea. Endocrinol Metab (Seoul) (2015) 0.75
Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats. Endocrine (2017) 0.75
Update on medical treatment for Cushing's disease. Clin Diabetes Endocrinol (2016) 0.75
Recent Progress in the Medical Therapy of Pituitary Tumors. Endocrinol Metab (Seoul) (2017) 0.75
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol (2008) 4.66
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol (2008) 3.43
Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol (2008) 3.32
Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab (2006) 3.13
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril (2002) 3.03
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA (2004) 2.93
Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril (2005) 2.90
Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab (2002) 2.76
Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause (2004) 2.69
Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem (2002) 2.61
Anti-Müllerian hormone: a new marker for ovarian function. Reproduction (2006) 2.49
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res (2010) 2.39
Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab (2005) 2.35
Severe hyponatremia with high urine sodium and osmolality. Clin Chem (2009) 2.22
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology (2005) 2.10
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol (2005) 2.07
The influence of corticosteroids on quantitative ultrasound parameters of the calcaneus in the 1st year after renal transplantation. Osteoporos Int (2004) 2.05
[Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis]. Ned Tijdschr Geneeskd (2015) 1.98
A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metab (2010) 1.98
Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. Am J Med (2004) 1.93
New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) (2009) 1.92
Thyroid hormone effects on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo. Endocrinology (2009) 1.90
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology (2012) 1.86
Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol (Oxf) (2003) 1.83
Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet (2012) 1.81
Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol (2003) 1.80
Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril (2002) 1.78
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol (2009) 1.78
High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab (2008) 1.77
Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) (2007) 1.77
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer (2010) 1.76
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol (2005) 1.75
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab (2010) 1.72
The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol (2006) 1.67
Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab (2005) 1.63
Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease. Clin Endocrinol (Oxf) (2004) 1.62
Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol (2008) 1.59
A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes (2002) 1.55
Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol (2009) 1.54
CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res (2003) 1.54
Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology (2006) 1.51
An age-dependent interaction with leptin unmasks ghrelin's bone-protective effects. Endocrinology (2012) 1.50
The role of routine diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer. J Nucl Med (2010) 1.50
Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab (2005) 1.49
Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology (2007) 1.49
Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex. Clin Chem (2005) 1.48
Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice. Endocrinology (2003) 1.47
Selective parasympathetic innervation of subcutaneous and intra-abdominal fat--functional implications. J Clin Invest (2002) 1.46
One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis. Intensive Care Med (2007) 1.46
Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol (2009) 1.45
Genetic determinants of serum testosterone concentrations in men. PLoS Genet (2011) 1.45
Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma. Thyroid (2011) 1.45
Clinical phenotype and mutant TRα1. N Engl J Med (2012) 1.43
SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab (2011) 1.42
Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab (2007) 1.42
Hepatocyte-specific IKKβ expression aggravates atherosclerosis development in APOE*3-Leiden mice. Atherosclerosis (2011) 1.42
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab (2008) 1.41
Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology (2006) 1.39
Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation (2010) 1.39
Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab (2004) 1.39
Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab (2008) 1.39
CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. J Lipid Res (2005) 1.35
Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) (2003) 1.34
Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nat Genet (2012) 1.34
Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod (2007) 1.33
Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod (2004) 1.32
Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models. Biochim Biophys Acta (2009) 1.32
Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J Clin Endocrinol Metab (2013) 1.32
The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J (2007) 1.31
Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms. PLoS Genet (2011) 1.30
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2012) 1.28
Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes (2003) 1.28
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res (2007) 1.27
Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer (2010) 1.26
Glucocorticoid receptor gene and risk of cardiovascular disease. Arch Intern Med (2008) 1.25
Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab (2005) 1.25
The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. Eur Heart J (2008) 1.24
Prediction of mortality risk in the elderly. Am J Med (2006) 1.24
Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum Reprod (2007) 1.23
Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med (2010) 1.23
Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab (2004) 1.23
A genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid hormone regulation. PLoS Genet (2012) 1.23
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging (2009) 1.23